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Abstract
Recent studies from Austria, France and Italy have shown that there is a poor adherence to the screening scheme
for maternal Toxoplasma infections in pregnancy demonstrated by the fact that many recommended examinations
are missed. This leads to undetected infections and limits our knowledge of incidence of the disease. We discuss
the negative consequences of this situation on research on treatment effectiveness and the outcomes of
congenital toxoplasmosis. The responsible public health institutions should assume responsibility for appropriate
surveillance of the screening programme and take measures to improve screening adherence during pregnancy.
Screening should start as early as possible in pregnancy and the latest test should be done at delivery. Screening
schedule should allow distinguishing infections from the first, second and third trimester of pregnancy, as the risk
of materno-foetal transmission and outcomes in case of foetal infections varies by time.
Background
Few conditions in medicine are more tragic than life-
long disabilities in children already acquired in preg-
nancy, like in congenital toxoplasmosis [1]. Some coun-
tries, most notably France and Austria, have engaged in
preventive programmes to fight this disease: These
countries were the first to implement population-wide,
free of cost prenatal screening programmes more than
three decades ago [2-4]. The idea of this approach is an
early detection of maternal infection in pregnancy to im-
plement the treatment as early as possible. Prenatal
screening must be clearly distinguished from neonatal
screening even if screening and treatment of newborns
have beneficial effects on the course of disease [5].
Given the long-lasting experience of prenatal screening
in France and Austria, there is comparably little epi-
demiological information from these countries about the
incidence of maternal infections. Not only epidemio-
logical research is hampered, but also the information is
lacking to assess the diagnostic performance of these
programmes. As stated in a recent review on the
epidemiology of toxoplasmosis in pregnancy: “The prime
example of minimal available data is France, . . .” [6].
Without doubt, this statement holds true for Austria as
well. Interestingly, both countries did not complement
their screening activities with appropriate surveillance
systems for congenital toxoplasmosis for about three
decades until at least France introduced mandatory
reporting in May 2007 [2].
This situation is disappointing as the treatment con-
cept has been questioned a few years ago. Despite earlier
promising findings [4,7], more recent multi-centre ob-
servational studies failed to confirm the effectiveness of
treatment provided during pregnancy [8-11]. In the con-
text of these discussions, Denmark and Switzerland have
stopped their nationwide screening programs for toxo-
plasmosis [12-14]. Although definitive answers on treat-
ment effectiveness can only be obtained from
randomized controlled studies [15], most recent publica-
tions provide arguments in favour of treatment effective-
ness [16-19]. It must be kept in mind regarding the
mentioned multi-centre studies that they cannot refute
the effectiveness of treatment, as a failure to reject the
null hypothesis does not mean that the alternative hy-
pothesis must be false. More importantly, many poten-
tial biases of these studies which could disguise true
effects have been discussed [20].
Why is it so difficult to determine the incidence of
maternal Toxoplasma infections in pregnancy in a
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country with a long-standing screening tradition? We
discuss problems encountered in the analysis of screen-
ing data from Austria.
Discussion
We recently reported in this journal a study to deter-
mine the incidence of maternal toxoplasmosis [21]. Our
analysis was based on data from the federal state of
Upper Austria for the time period 2000 to 2007. Based
on these experiences, we formulate some general
requirements for a database from serological laboratories
which would allow assessing the seroprevalence and in-
cidence of primoinfections in pregnancy:
1. a defined catchment area
2. a defined study period (taking into consideration
that pregnancy is a time period)
3. unique personal identifiers
4. age of the tested person (because of age dependency
of seroprevalence!)
5. information about rural or urban residence
6. information about social status (if probability to be
included into the study might depend on social
factors as it can be the case for immigrants)
7. appropriate serological screening techniques
8. confirmatory testing from reference laboratory if
infection is suspected by screening methods
9. standard specimen sampling scheme
10.information about gestational week and parity
11.first test as soon as possible in early pregnancy
12.latest test conducted at birth
Fortunately, the retrospectively available data from
Upper Austria fulfilled many of these requirements:
Using data from a single laboratory, we had access not
to all but most of pregnant women of this federal state
and to their personal identifiers. In contrast, there would
be problems in other settings in Austria, as in many fed-
eral states several laboratories conduct screening for
toxoplasmosis and data exchange is difficult due to the
strict data protection regulations. Information on social
factors was less important, as the study population was
from all social classes. The diagnostic techniques were
almost identical (single laboratory) and unchanged dur-
ing the study period (indirect immunofluorescent test
was replaced by another immunoassay in 2008, i.e. after
the end of the study period).
A severe problem was the poor compliance with the
screening scheme: Only about 30% of seronegative preg-
nant women had all three or more recommended tests.
Apparently, this is problem is not restricted to Upper
Austria: A recent study from a region in south-east
France reported that only 40% of seronegative pregnant
women had all seven or more screening tests according
to the French scheme [22]. According to the authors,
this was the first study to evaluate the compliance with
the screening scheme in France. From northern Italy, ad-
herence of less than 35% with recommended five or
more screening tests was reported [23]. With regard to
Austria, we are not aware of previous studies that
addressed this problem.
We believe that predominantly tests in the late preg-
nancy were neglected in Austria: The general prenatal
care programme (mother child pass, issued by Austrian
Ministry of Health) schedules routine blood sampling
before the 16th gestational week (erythrocyte count,
haemoglobin, blood group, Rhesus factor, serology for
rubella immunity, Treponema pallidum and Toxo-
plasma gondii) and between the 25th to 28th gestational
weeks (erythrocyte count, haemoglobin, Hepatitis B
surface antigen and Toxoplasma gondii) if the woman
was seronegative in the previous test. There is some
small space to record additional blood tests in the pre-
natal care booklet for additional tests on toxoplasmosis,
but it must be remembered by the gynaecologist if
(previous tests seronegative) and when (recommenda-
tion: 8th gestational month) to do so. Based on the
analysis, we assume that many seronegative pregnan-
cies had no further serological testing for Toxoplasma
infection beyond the 28th gestational week (except for
some hospitals voluntarily testing at delivery, but these
results are not accessible for data analysis). As our
dataset did not contain information about the gesta-
tional week, we could not check this hypothesis. As a
result of missing tests in the late pregnancy, large peri-
ods between the corresponding latest examinations and
births remained “blind” i.e. it was not known whether
infections occurred. These periods were under risk for
congenital toxoplasmosis and a recent study empha-
sised the importance of infections in late pregnancy
and of testing at delivery [24].
With long time periods without a diagnostic test
(“blind periods”), it is impossible to calculate incidence
from observed data only. We used two different regres-
sion models to estimate incidence and considered their
limitations and biases. The estimates showed that inci-
dence calculated from laboratory results of proven infec-
tions only suffered from severe underreporting.
In 1992, the leading Austrian toxoplasmosis experts H.
Aspöck and A. Pollak presented rates of suspected infec-
tions from 1981 to 1991 referred to routine examina-
tions from their laboratories [4]. “. . ., in 0.68% a primary
infection during pregnancy was suspected, and in 0.32%
already at the first test.” Noteworthy, about half of sus-
pected infections were made at the first test. Usually the
first test is made early in the first trimester and we
would expect no more than about a third of all infec-
tions to occur in this period. Probably the problem of
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poor compliance with screening in the late pregnancy
already existed in the 1980’s. This view is supported by
the authors’ uncommented postulate [4]: “Close observa-
tion of the recommended time-table for blood sampling
and the testing criteria.”
“Blind periods” at the end of pregnancy unfortunately
miss those infections that are easy to diagnose, while
suspected infections in the first test in pregnancy are dif-
ficult to confirm even by reference laboratories [25]. In
contrast, seroconversions during pregnancy are easily
determined if women were seronegative in early preg-
nancy. With regard to the diagnostic difficulties with
suspected infections in the first test, it is important to
do the first test as early as possible in pregnancy to keep
the diagnostically difficult period from conception until
the first test short.
“Blind periods” produce further problems: Toxoplasma
infections are dangerous during any time in pregnancy,
but the risks of transmission to the foetus and the result-
ing clinical affections differ from trimester to trimester
[26]. Any analysis of outcomes of congenital toxoplas-
mosis will be limited, if some periods of pregnancy are
underrepresented in assessment of infections.
Chêne and Thiébaut [27] explained the need for new
treatment trials and estimated that about 260 – 350
acute infections, for example, in the second or third tri-
mester of pregnancy have to be included per arm for a
reasonable comparison of prenatal treatment with
pyrimethamine-sulphadiazine to spiramycine. The
authors also suggested a less demanding, placebo-
controlled study, but in our view, placebo controlled
study is not possible for ethical reasons. The Federal
State of Upper Austria with a total population of 1.4 mil-
lion inhabitants (= 1/6 of the Austrian population),
could theoretically contribute about 118 – 196 cases of
acute infection within an eight-year period for treatment
trials, if incidence remains stable and if all infections
were detected and included in the study.
In 2010, a multicentre study of 293 cases of congenital
toxoplasmosis collected from six European countries
investigated treatment effects on development of serious
neurological sequelae [19]. The authors want their
results to “be interpreted with caution because of the
low number of . . . cases and uncertainty about the tim-
ing of maternal seroconversion.” Again, this attempt
underlines the need to improve adherence to appropriate
screening intervals and documentation of gestational
week when screening test is conducted.
What has to be done? Austrian public health decision
makers should assume responsibility for their prenatal
toxoplasmosis screening program. Its performance
should be assured by an appropriate epidemiological sur-
veillance. Therefore, necessary information should be
provided by prenatal care doctors, collected in electronic
data sets and evaluated by public health epidemiologists.
Doctors who miss recommended examinations should
receive a reminder in order to improve their testing
adherence.
In addition, the screening scheme should be modified
to provide optimum coverage of the entire pregnancy
from the very first visit of the pregnant woman in a pre-
natal care facility until birth. Screening intervals should
at least distinguish the three trimesters of pregnancy.
Keeping the gap between infection and diagnosis/treat-
ment close, shorter intervals have been proposed [28],
however economical analyses are needed to assess the
cost-effectiveness of the added value of more frequent
testing.
Any further research on follow-up in congenital toxo-
plasmosis and on efficacy of prenatal treatment would
improve with complete registration of prenatal Toxo-
plasma infections given that the disease of interest is
rare and that risks and outcomes of infection differ by
the trimester of pregnancy.
Summary
“Blind periods” in prenatal screening of Toxoplasma
infections lead to missed infections and limit our know-
ledge of their incidence. This compromises research on
treatment effectiveness and outcomes of congenital
toxoplasmosis. “Blind periods” can be avoided by appro-
priate surveillance of the screening programme. For
optimum evaluation, a minimum of electronically
recorded data about the serological tests including gesta-
tional week, parity and unique personal identifiers are
needed.
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